Clinical Trials
25 trialsNCT03971409 2026-04-17
InCITe
University of California, San Francisco
Phase 2 Active not recruiting
NCT03964532 2026-04-09
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Georgetown University
Phase 1/2 Active not recruiting
NCT04841148 2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04360941 2026-04-06
PAveMenT
Royal Marsden NHS Foundation Trust
Phase 1 Recruiting
NCT03573648 2026-03-19
ImmunoADAPT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT02926196 2025-12-12
A-Brave
Istituto Oncologico Veneto IRCCS
Phase 3 Completed
NCT04188119 2025-12-08
IMpALA
The Christie NHS Foundation Trust
Phase 2 Withdrawn
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT03147287 2025-09-30
Palbociclib After CDK and Endocrine Therapy (PACE)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03414658 2025-07-02
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03175666 2025-02-21
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03554109 2025-02-21
TNBC
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT04215146 2025-01-16
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Oncolytics Biotech
Phase 2 Active not recruiting
NCT03387085 2024-08-09
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02554812 2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2 Terminated
NCT03861403 2023-11-30
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Phase 1 Terminated
NCT03330405 2023-10-13
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT04551885 2023-09-21
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT02630368 2022-02-02
METROmaJX
Institut Bergonié
Phase 1/2 Unknown
NCT01772004 2021-12-20
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
EMD Serono
Phase 1 Completed
NCT02222922 2020-12-17
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03794596 2019-07-22
IMpALA
The Christie NHS Foundation Trust
Phase 2 Withdrawn